摘要
Abstract
Objective To compare the curative effects and pharmacoeconomic costs of 3 therapeutic schemes in the treatment of type 2 diabetes mellitus. Methods By a retrospective survey method, 150 cases of type 2 diabetes mellitus patients were randomly divided into 3 groups. The 50 patients in group A were given Metformin hydrochloride sustained-release tablets, the 50 patients in group B were given Acarbose tablets, and the 50 patients in group C were given Mitiglinide calcium tablets for 12 weeks. The levels of fasting blood glucose (FBG), 2-h postprandial blood glucose (PBG) and HbA1c were observed in the 3 groups before and after treatment. The cost-effectiveness was evaluated by pharmacoeconomic method. Results After 12 weeks, the FPG, 2-h PBG and HbAlc of the 3 groups were decreased to some extent. The costs of the 3 therapeutic schemes were 208.32, 529.20 and 609.84 yuan, respectively. The total effective rate of the groups A, B and C were 70.00%, 74.00% and 82.00%, respectively. The cost-effectiveness ratio of the groups A, B and C was 2.98, 7.15 and 7.44 respectively. Using the group A as a reference, ∆C/∆E for the groups B and C were 80.22 and 33.46 yuan respectively. Conclusions Among the 3 therapeutic schemes, Mitiglinide for the group C has pharmacoeconomic advantage in treating type 2 diabetes mellitus.关键词
2型糖尿病/成本- 效果分析/药物经济学Key words
type 2 diabetes mellitus/cost-effectiveness analysis/pharmacoeconomics分类
医药卫生
